Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
Pfizer's Phase 2 study of ponsegromab met primary endpoint, showing 5.6% mean body weight increase at highest dose in cancer cachexia patients. Improvements in appetite, cachexia symptoms, physical activity, and muscle mass were observed. Ponsegromab was safe and well-tolerated. Registration-enabling studies are planned for 2025.
Related Clinical Trials
Reference News
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
Pfizer's Phase 2 study of ponsegromab met primary endpoint, showing 5.6% mean body weight increase at highest dose in cancer cachexia patients. Improvements in appetite, cachexia symptoms, physical activity, and muscle mass were observed. Ponsegromab was safe and well-tolerated. Registration-enabling studies are planned for 2025.